+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SAAKSHI

Saakshi Medtech & Panels Share Price

 

 

Saakshi Medtech & Panels live price: ₹302.4. It opened at ₹293 vs previous close ₹295; intraday high/low: ₹302/₹293. The 50 & 200 DMA stand at ₹264.13/₹216.25.

Saakshi Medtech & Panels Performance

  • Today's Low
  • ₹293
  • Today's High
  • ₹302
  • 52 Week Low
  • ₹147
  • 52 Week High
  • ₹331
  • Open Price₹293
  • Previous Close₹295
  • Volume7,200
  • 50 DMA₹264.13
  • 100 DMA₹238.92
  • 200 DMA₹216.25

Saakshi Medtech & Panels Chart

Investment Returns

  • Over 1 Month + 18.84%
  • Over 3 Month + 56.68%
  • Over 6 Month + 81.19%
  • Over 1 Year + 52.11%

Smart Investing Starts Here Start SIP with Saakshi Medtech & Panels for Steady Growth!

Invest Now

Saakshi Medtech & Panels Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 43.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 534
  • P/B Ratio
  • 4.8
  • Average True Range
  • 13.81
  • EPS
  • 6.96
  • Dividend Yield
  • 0
  • MACD Signal
  • 14.49
  • RSI
  • 59.93
  • MFI
  • 60.17

Latest Stock News Updates

Saakshi Medtech shares make stellar debut, stock lists at 50.5% premium at 146 on NSE SME

Saakshi Medtech shares make stellar debut on NSE SME, listed at 146 per share, 50.5% higher than issue price of 97.

Saakshi Medtech & Panels Financials

Saakshi Medtech & Panels Technicals

EMA & SMA

Current Price
₹302.40
+ 7.35 (2.49%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹288.90
  • 50 Day
  • ₹264.10
  • 100 Day
  • ₹238.90
  • 200 Day
  • ₹216.20

Resistance and Support

299.27 Pivot Speed
  • R3 314.93
  • R2 308.67
  • R1 305.53
  • S1 296.13
  • S2 289.87
  • S3 286.73

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Saakshi Medtech And Panels Ltd has an operating revenue of Rs. 281.82 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 46% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 6% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Saakshi Medtech & Panels Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results
2026-05-07 To consider Fund Raising
2025-11-14 Quarterly Results
2024-11-13 Quarterly Results
2024-05-28 Audited Results

Saakshi Medtech & Panels Shareholding Pattern

74.82%
0.07%
21.17%
3.94%

Saakshi Medtech & Panels FAQs

Saakshi Medtech & Panels share price is ₹302 As on 14 July, 2026 | 00:19

The Market Cap of Saakshi Medtech & Panels is ₹533.9 Cr As on 14 July, 2026 | 00:19

The P/E ratio of Saakshi Medtech & Panels is 43.4 As on 14 July, 2026 | 00:19

The PB ratio of Saakshi Medtech & Panels is 4.8 As on 14 July, 2026 | 00:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23